Axinn partner Stacie Ropka presented at ACI's 8th annual Summit on Biosimilars in New York City.
Stacie Ropka participated in a panel entitled, "Shall we Dance: Mastering the 'Steps' of the BPCIA While Avoiding Common Pitfalls." This interactive session delved into the decision-making process for each step along the way from decision to go through the BPCIA, to litigation strategies, to product launch and marketing. The audience divided into small “working groups” each with a moderator. Topics included the possible impact of Amgen v. Sandoz on the patent dance; strategically timing the filing of a biosimilar application in light of 180-day notice provision and tips for minimizing litigation risks for biosimilars applicants.